Association study between genetic variants at the PIP5K2A gene locus and schizophrenia and bipolar affective disorder

Results from molecular and pharmacological studies point to involvement of the gene coding for the phosphatidylinositol‐4‐phosphate 5‐kinase type II‐alpha (PIP5K2A) in the development of schizophrenia and bipolar affective disorder (BPAD). The PIP5K2A gene locus, which is located on chromosomal regi...

Full description

Saved in:
Bibliographic Details
Published in:American journal of medical genetics. Part B, Neuropsychiatric genetics Neuropsychiatric genetics, 2006-09, Vol.141B (6), p.663-665
Main Authors: Jamra, Rami Abou, Klein, Katrin, Villela, Angela Wolf, Becker, Tim, Schulze, Thomas G., Schmael, Christine, Deschner, Monika, Klopp, Norman, Illig, Thomas, Propping, Peter, Cichon, Sven, Rietschel, Marcella, Nöthen, Markus M., Schumacher, Johannes
Format: Article
Language:English
Subjects:
10p12
Adult and adolescent clinical studies
Biological and medical sciences
Bipolar Disorder - genetics
case-control
Case-Control Studies
Genetic Markers
Genetic Variation
German
Humans
Medical sciences
Miscellaneous
Mood disorders
phosphatidylinositol-4-phosphate 5-kinase type II-alpha
Phosphotransferases (Alcohol Group Acceptor) - genetics
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Schizophrenia
Schizophrenia - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Results from molecular and pharmacological studies point to involvement of the gene coding for the phosphatidylinositol‐4‐phosphate 5‐kinase type II‐alpha (PIP5K2A) in the development of schizophrenia and bipolar affective disorder (BPAD). The PIP5K2A gene locus, which is located on chromosomal region 10p12, has been implicated in the development of both disorders by independent linkage and association studies. On a cellular level, PIP5K2A is an enzyme component of the metabolism of inositol phosphate, which has been considered a potential target for the therapeutic action of lithium in BPAD patients. Given that the PIP5K2A gene is a promising candidate for the development of both disorders, we performed an association study between genetic variants at the PIP5K2A locus and 268 patients with schizophrenia, 260 patients with BPAD and 325 ethnically matched healthy controls. We failed to detect association to either disorder using PIP5K2A gene variants through single‐marker and haplotype analysis. Therefore, our data does not support an involvement of the PIP5K2A locus in the etiology of either schizophrenia or BPAD in the German population. © 2006 Wiley‐Liss, Inc.
ISSN:1552-4841
1552-485X
DOI:10.1002/ajmg.b.30358